2 completed, 1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 3 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Transfusion Dependent Beta Thalassemia: new trials by email Literature Review of Transfusion Dependent Beta Thalassemia trials Research Report on Transfusion Dependent Beta Thalassemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia YOLT-204 - Transfusion Dependent Beta Thalassemia | Early Phase 1 | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 3 | 2024-12-31 | 2024-11-07 |
| Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin) - Transfusion Dependent Beta Thalassemia | Phase 2 | Completed | Ain Shams University | 80 | 2024-11-22 | 2026-01-27 |
| Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy Transfusion Dependent Beta Thalassemia, Sickle Cell Disease | Enrolling by invitation | Georgetown University | 100 | 2024-10-01 | 2024-10-29 | |
| Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia ADDITION OF THALIDOMIDE AND HYDROXYUREA - Transfusion Dependent Beta Thalassemia | Phase 2 | Completed | Pakistan Blood and Marrow Transplant (PBMT) Group | 100 | 2024-01-01 | 2026-05-05 |
| EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) EDIT-301 - Transfusion Dependent Beta Thalassemia, Hemoglobinopathies | Phase 1 / Phase 2 | Active not recruiting | Editas Medicine, Inc. | 9 | 2022-04-29 | 2025-04-02 |
Anemia, Sickle Cell (1) · Diabetes Mellitus (1) · Hemoglobinopathies (1) · beta-Thalassemia (1)
Anemia (2) · Anemia, Hemolytic (2) · Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Hemoglobinopathies (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Thalassemia (1)
Control Groups (1) · Hydroxyurea (1) · Insulin (1) · Thalidomide (1) · dulaglutide (1)
Ain Shams University (1) · Editas Medicine, Inc. (1) · First Affiliated Hospital of Guangxi Medical University (1) · Georgetown University (1) · Pakistan Blood and Marrow Transplant (PBMT) Group (1)
United States (2) · Canada (1) · China (1) · Egypt (1) · Pakistan (1)
PMID 28850716, PMID 32425398, PMID 34456732, PMID 35477175, PMID 36699430, PMID 41931048, PMID 42618811